Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
-
Narrated by:
-
Written by:
About this listen
Brandon Ko, NP, a pediatric rheumatology nurse practitioner at the University of New Mexico and Pediatric Chair for RhAPP, reviews the potential role of guselkumab in juvenile psoriatic arthritis. This medication review explores the current FDA submission for pediatric use, the clinical rationale behind extrapolating adult psoriatic arthritis data, and supporting safety and efficacy findings from pediatric plaque psoriasis studies. The discussion highlights where guselkumab may fit among existing treatment options for juvenile psoriatic arthritis, including TNF inhibitors, IL-17 inhibitors, JAK inhibitors, and other biologics, while addressing key considerations such as disease severity, treatment sequencing, and uveitis risk. Designed for rheumatology APPs and clinicians, this overview provides timely insight into emerging pediatric treatment options and what FDA approval could mean for patient care.